CeriBell, Inc. (CBLL)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 26 | 45 | 65 | 89 | 102 | 116 |
| Operating profit | $m | -58 | -70 | ||||||
| Net profit | $m | - | - | -37 | -29 | -40 | -53 | -66 | -75 |
| EPS reported | $ | -1.46 | -1.76 | ||||||
| Operating cashflow per share | $ | -1.12 | -1.42 | ||||||
| Capex per share | $ | 0.02 | 0.06 | ||||||
| FCF per share | $ | -1.14 | -1.48 | ||||||
| Free cash flow | $m | -42 | -56 | ||||||
| Net debt | $m | -139 | -109 | ||||||
| Book value equity | $m | 155 | 128 | ||||||
| Book value per share | $ | 4.25 | 3.37 | ||||||
| Number of shares | m | 36.54 | 38.03 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 5.16 | 6.25 | ||||||
| P/S LTM | x | 9.00 | 7.86 | ||||||
| P/FCF LTM | x | -19.28 | -14.23 | ||||||
| EV/EBITDA LTM | x | -15.61 | -12.42 | ||||||
| EV/Sales LTM | x | 8.79 | 9.09 | ||||||
| Earnings Yield LTM | % | -6.67% | -7.02% | ||||||
| FCF Yield | % | -5.19% | -7.03% | ||||||
| Quality | |||||||||
| ROE | % | -34.38% | -44.85% | ||||||
| ROIC | % | -32.86% | -46.54% | ||||||
| Operating margin | % | -65.57% | -68.62% | ||||||
| Gross margin | % | +87.89% | +88.90% | ||||||
| FCF/Sales | % | -46.68% | -55.25% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +36.09% | +55.80% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.87 | -2.57 | ||||||
| Net Debt/EBITDA | x | 0.36 | 0.17 | ||||||
| EBIT/Net interest | x | -30.90 | -38.57 | ||||||
| Net debt/market cap | % | +2.47% | +2.26% | ||||||
| Net debt/Equity | x | -0.90 | -0.85 | ||||||
| Gross debt/equity | x | 0.14 | 0.17 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free